Dipartimento di Scienze Mediche, Università degli Studi di Milano, Italy.
Mol Cell Endocrinol. 2010 Jun 30;322(1-2):72-82. doi: 10.1016/j.mce.2010.01.008. Epub 2010 Jan 18.
The resistance to thyrotropin (TSH) action is the disease associated with molecular defects hampering the adequate transmission of TSH stimulatory signal into thyroid cells. The defect may in principle affect every step along the cascade of events following the binding of TSH to its receptor (TSHR) on thyroid cell membranes. After the description of the first family affected with loss-of-function (LOF) TSHR mutations in 1995, there is now evidence that TSH resistance is a disease with a broad range of expressivity going from severe congenital hypothyroidism (CH) with thyroid hypoplasia to mild hyperthyrotropinemia (hyperTSH) associated with an apparent euthyroid state. More severe forms occur in patients with disrupting biallelic TSHR mutations and follow a recessive pattern of inheritance. Differential diagnosis in these cases includes the exclusion of other causes of thyroid dysgenesis, such as mutations in thyroid transcription factors. More mild forms may instead occur in patients with monoallelic TSHR defects following a dominant mode of inheritance. In these cases we described the dominant negative effect exerted by some LOF mutants on the activity of the wild-type TSHR. Differential diagnosis involves the exclusion of mild hypothyroidism in autoimmune thyroid disease or pseudohypoparathyroidism associated with genetic or epigenetic defects at the GNAS locus. This review will focus on the prevalence of TSHR mutations, on the molecular mechanisms leading to TSH resistance and on the variable clinical expression of this disease.
促甲状腺激素(TSH)作用抵抗是一种与分子缺陷相关的疾病,这些缺陷阻碍了 TSH 刺激信号在甲状腺细胞中的充分传递。该缺陷原则上可能影响 TSH 与其在甲状腺细胞膜上的受体(TSHR)结合后沿着级联事件的每一步。在 1995 年首次描述了丧失功能(LOF)TSHR 突变的第一个受影响家族之后,现在有证据表明 TSH 抵抗是一种具有广泛表达性的疾病,从严重的先天性甲状腺功能减退症(CH)伴甲状腺发育不全到轻度高促甲状腺激素血症(hyperTSH)伴明显的甲状腺功能正常状态。更严重的形式发生在具有破坏性双等位 TSHR 突变的患者中,并遵循隐性遗传模式。在这些情况下,鉴别诊断包括排除其他甲状腺发育不全的原因,如甲状腺转录因子的突变。相反,更轻微的形式可能发生在具有单等位 TSHR 缺陷的患者中,遗传模式为显性。在这些情况下,我们描述了一些 LOF 突变对野生型 TSHR 活性的显性负效应。鉴别诊断包括排除自身免疫性甲状腺疾病或与 GNAS 基因座的遗传或表观遗传缺陷相关的假性甲状旁腺功能减退症中的轻度甲状腺功能减退症。本综述将重点讨论 TSHR 突变的流行率、导致 TSH 抵抗的分子机制以及这种疾病的可变临床表达。